CytomX Therapeutics Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript
Hi, my name is Mitchell Kapoor, and I'd like to welcome you to the HC Wainwright Immune Cell Engager Conference. I'm a senior biotech analyst here at H.C. Wainwright and I'm pleased to be joined by Sean McCarthy, the CEO of CytomX. Thank you for joining, Sean.
Thanks, much. Great to be honour.
So, maybe we can start off just giving an overview of this iconic story for those who are new to the story.
Yes, sure. Happy to do. So, we've been working in the field of conditional activation of therapeutic antibodies now for more than a decade. We've really pioneered this field. And our thesis is that as biologic formats have become increasingly potent in order to drive greater and greater anti-tumor efficacy, we've seen toxicities tend to track that increase in both potency.
Our view is that we need new methodologies for new approaches to improving therapeutic window and directing biologic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
